News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neurizon Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
PharmAust’s monepantel drug could be a game-changer for MND/ALS patients, new data shows
News
ASX Small Caps Lunch Wrap: Who somehow managed to be shocked by a Madonna concert this week?
News
Top 10 at 10: Kava stock bags on sales blitz, Treasury Wines pops corks on guidance update
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: ASX rebounds 1.6pc in May; Guzman y Gomez talks IPO fiesta
Health & Biotech
PharmAust puts experienced hands back on its rudder
Health & Biotech
ASX Health Stocks: AVITA soars on FDA green light for RECELL GO System
Health & Biotech
‘Outstanding milestone’: FDA grants PharmAust orphan drug designation for monepantel
News
Closing Bell: Market mood swings as ASX tumbles, iron ore and lithium miners rise on China hopes
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
PharmAust plans for pivotal Phase 2/3 trial after key quarter of milestones
Health & Biotech
PharmAust bolsters manufacturing leadership to expand path to commercialisation
Health & Biotech
Which ASX companies are resurrecting abandoned drugs? Part 1
Health & Biotech
PharmAust inks approval from Macquarie University for Open-Label MND extension study
Health & Biotech
ASX Health Winners March: A rebound? Aussie biotech sector is on the radar of Asian investors
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
